Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Fig. 2

Kaplan-Meier survival plots of mCRPC patients. The survival differences were compared among four risk groups which was stratified according to the status of CTCs (absence/presence) and NLR level (low/high) (A for PFS analysis and B for OS analysis), or according to the status of CTCs (absence/presence) and PLR level (low/high) (C for PFS analysis and D for OS analysis). Survival differences were compared with the log rank test, with P < 0.05 denoting significance. mCRPC: metastatic castration-resistant prostate cancer; CTC: circulating tumor cell; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; PFS: progression-free survival; OS: overall survival

Back to article page